CARISMA Therapeutics Enters Into Scientific Research and Licensing Agreement With NYU Langone Health, Gains Exclusive Rights to Vpx Lentiviral Vector

August 25, 2020

PHILADELPHIAAug. 25, 2020 /PRNewswire/ — CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, today announced it has entered into a scientific research and licensing agreement with Nathaniel R. Landau, PhD and NYU Langone Health through which CARISMA will attain exclusive rights to develop and commercialize their Vpx lentiviral vector globally for all indications. The Vpx lentiviral and CARISMA’s Ad5f35 vectors are the only two vectors known to be effective in engineering macrophages, a pivotal aspect of CARISMA’s approach. Click here to read more.